NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Start Multiple Choice Practice Test
Start Flash Cards

Practice this question and more.

Omalizumab (Xolair) is indicated for?

  1. Moderate-severe persistent allergic asthma

  2. Chronic obstructive pulmonary disease (COPD)

  3. Mild intermittent asthma

  4. Acute asthma attacks

The correct answer is: Moderate-severe persistent allergic asthma

Omalizumab (Xolair) is indicated for moderate-severe persistent allergic asthma. It is a monoclonal antibody that is specifically approved for use in patients with allergic asthma that is not controlled with inhaled corticosteroids. The drug works by blocking immunoglobulin E (IgE), which is responsible for triggering allergic reactions in the body. Therefore, option A is the correct choice as it accurately reflects the approved indication for omalizumab. Options B, C, and D are incorrect: B. Chronic obstructive pulmonary disease (COPD): Omalizumab is not indicated for COPD as it is specifically approved for allergic asthma. C. Mild intermittent asthma: Omalizumab is used for moderate-severe persistent allergic asthma, not for mild intermittent asthma. D. Acute asthma attacks: Omalizumab is not used for acute asthma attacks, rather it is a long-term controller medication for persistent allergic asthma.

More Questions Like This